These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 14605126)

  • 21. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral therapy in Abidjan, Côte d'Ivoire.
    Adjé C; Cheingsong R; Roels TH; Maurice C; Djomand G; Verbiest W; Hertogs K; Larder B; Monga B; Peeters M; Eholie S; Bissagene E; Coulibaly M; Respess R; Wiktor SZ; Chorba T; Nkengasong JN;
    J Acquir Immune Defic Syndr; 2001 Apr; 26(5):501-6. PubMed ID: 11391173
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Performance of drug-resistance genotypic assays among HIV-1 infected patients with predominantly CRF02_AG strains of HIV-1 in Abidjan, Cote d'Ivoire.
    Bilé EC; Adjé-Touré C; Borget MY; Kalou M; Diomande F; Chorba T; Nkengasong JN
    J Clin Virol; 2005 Jan; 32(1):60-6. PubMed ID: 15572008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phenotypic and genotypic resistance to nucleoside reverse transcriptase inhibitors in HIV-1 clinical isolates.
    Lafeuillade A; Poggi C; Hittinger G; Chadapaud S
    HIV Med; 2001 Oct; 2(4):231-5. PubMed ID: 11737402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV type-1 genotypic resistance profiles in vertically infected patients from Argentina reveal an association between K103N+L100I and L74V mutations.
    Aulicino PC; Rocco CA; Mecikovsky D; Bologna R; Mangano A; Sen L
    Antivir Ther; 2010; 15(4):641-50. PubMed ID: 20587857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vivo emergence of drug-resistant mutations at less than 50 HIV-1 RNA copies/mL that are maintained at viral rebound in longitudinal plasma samples from human immunodeficiency virus type-1-infected patients on highly active antiretroviral therapy.
    Elbeik T; Hoo BS; Campodonico ME; Dileanis J; Fay FF; Bortolozzi RL; Benetti MS; Fay OH; Marlowe N; Petrauskene O; Chernoff D; Smith L; Ng VL
    J Hum Virol; 2001; 4(6):317-28. PubMed ID: 12082398
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced antiretroviral drug susceptibility among patients with primary HIV infection.
    Little SJ; Daar ES; D'Aquila RT; Keiser PH; Connick E; Whitcomb JM; Hellmann NS; Petropoulos CJ; Sutton L; Pitt JA; Rosenberg ES; Koup RA; Walker BD; Richman DD
    JAMA; 1999 Sep 22-29; 282(12):1142-9. PubMed ID: 10501117
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection.
    Vasudevachari MB; Zhang YM; Imamichi H; Imamichi T; Falloon J; Salzman NP
    Antimicrob Agents Chemother; 1996 Nov; 40(11):2535-41. PubMed ID: 8913459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantification of the effects on viral DNA synthesis of reverse transcriptase mutations conferring human immunodeficiency virus type 1 resistance to nucleoside analogues.
    Bouchonnet F; Dam E; Mammano F; de Soultrait V; Henneré G; Benech H; Clavel F; Hance AJ
    J Virol; 2005 Jan; 79(2):812-22. PubMed ID: 15613309
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of HIV drug resistance mutation in the northern Indian population after failure of the first line antiretroviral therapy.
    Sinha S; Shekhar RC; Ahmad H; Kumar N; Samantaray JC; Sreenivas V; Khan NH; Mitsuyasu RT
    Curr HIV Res; 2012 Sep; 10(6):532-8. PubMed ID: 22716105
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HIV-1 drug resistance in newly infected individuals.
    Boden D; Hurley A; Zhang L; Cao Y; Guo Y; Jones E; Tsay J; Ip J; Farthing C; Limoli K; Parkin N; Markowitz M
    JAMA; 1999 Sep 22-29; 282(12):1135-41. PubMed ID: 10501116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.
    Grossman Z; Paxinos EE; Averbuch D; Maayan S; Parkin NT; Engelhard D; Lorber M; Istomin V; Shaked Y; Mendelson E; Ram D; Petropoulos CJ; Schapiro JM
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2159-65. PubMed ID: 15155216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Performance of an in-house genotypic antiretroviral resistance assay in patients pretreated with multiple human immunodeficiency virus type 1 protease and reverse transcriptase inhibitors.
    Peduzzi C; Pierotti P; Venturi G; Romano L; Mazzotta F; Zazzi M
    J Clin Virol; 2002 Jul; 25(1):57-62. PubMed ID: 12126722
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selection of mutations in the connection and RNase H domains of human immunodeficiency virus type 1 reverse transcriptase that increase resistance to 3'-azido-3'-dideoxythymidine.
    Brehm JH; Koontz D; Meteer JD; Pathak V; Sluis-Cremer N; Mellors JW
    J Virol; 2007 Aug; 81(15):7852-9. PubMed ID: 17507476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study.
    Salomon H; Wainberg MA; Brenner B; Quan Y; Rouleau D; Coté P; LeBlanc R; Lefebvre E; Spira B; Tsoukas C; Sekaly RP; Conway B; Mayers D; Routy JP
    AIDS; 2000 Jan; 14(2):F17-23. PubMed ID: 10708278
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutation patterns of the reverse transcriptase genes in HIV-1 infected patients receiving combinations of nucleoside and non nucleoside inhibitors.
    Re MC; Bon I; Monari P; Borderi M; Gibellini D; Schiavone P; Vitone F; Chiodo F; La Placa M
    Int J Antimicrob Agents; 2003 Oct; 22(4):388-94. PubMed ID: 14522102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of HIV-1 polymerase gene mutations in pre-treated patients in Thailand.
    Chantratita W; Jenwitheesuk E; Watitpun C; Pongthanapisith V; Vibhagool A; Leechawengwong M; Sookpranee M; Apairatana A
    Southeast Asian J Trop Med Public Health; 2002 Mar; 33(1):80-4. PubMed ID: 12118466
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ultra-deep sequencing improves the detection of drug resistance in cellular DNA from HIV-infected patients on ART with suppressed viraemia.
    Rodriguez C; Nere ML; Demontant V; Charreau I; Mercier-Darty M; Delagreverie H; Salmona M; de Castro N; Chaix ML; Molina JM; Delaugerre C
    J Antimicrob Chemother; 2018 Nov; 73(11):3122-3128. PubMed ID: 30137335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1.
    Hu Z; Giguel F; Hatano H; Reid P; Lu J; Kuritzkes DR
    J Virol; 2006 Jul; 80(14):7020-7. PubMed ID: 16809307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.